Tag: Merck
-
India revokes patent for Merck asthma drug – Economic Times
Economic Times India revokes patent for Merck asthma drugEconomic TimesNEW DELHI: India has revoked a patent for an asthma drug held by US-based Merck following a challenge from local pharmaceutical giant Cipla, marking a new blow to global drug firms in the Indian market. The development is the latest in a string of …India revokes…
-
India revokes patent on Merck & Co asthma drug – Yahoo! News (blog)
India revokes patent on Merck & Co asthma drugYahoo! News (blog)MUMBAI (Reuters) – India has revoked a patent granted to an asthma drug made by Schering Corp, later bought by U.S.-based Merck & Co, citing lack of invention, after Indian drugmaker Cipla Ltd challenged an earlier decision. The move is the latest in a ……
-
India revokes patent on Merck & Co asthma drug – Reuters
India revokes patent on Merck & Co asthma drugReutersMUMBAI (Reuters) – India has revoked a patent granted to an asthma drug made by Schering Corp, later bought by U.S.-based Merck & Co, citing lack of invention, after Indian drugmaker Cipla Ltd challenged an earlier decision. The move is the latest in a …and more » View…
-
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Washington Post
Proactive Investors USA & Canada Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …Washington PostDrugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair. The maker of diabetes pill…
-
Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma … – Newser
Globe and Mail Merck 3Q profit up 2 pct despite sales dip from generic competition to asthma …NewserThe maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30. Merck, based…
-
Merck & Co’s asthma drug Singulair faces US generic onslaught – PMLiVE
MedPage Today Merck & Co's asthma drug Singulair faces US generic onslaughtPMLiVEThe Food and Drug Administration (FDA) has approved the first generic versions of Merck & Co's blockbuster asthma and allergy drug Singulair. The US regulator granted ten companies licences to market their own version of Singulair (motelukast) for use …Israel : TEVA bags approval…
-
Merck Frosst loses information-protection appeal – Vancouver Sun
Merck Frosst loses information-protection appealVancouver SunThe Supreme Court of Canada on Friday ruled that the federal government was entitled to release information the company had given it about an asthma drug more than a decade ago. "Merck has not shown that the Federal Court of Appeal erred in the …and more » View full post on…
-
Merck settles Mass. Medicaid fraud claims for $24M – Sacramento Bee
Merck settles Mass. Medicaid fraud claims for $24MSacramento BeeAP BOSTON — Drugmaker Merck & Co. will pay Massachusetts $24 million to settle a civil lawsuit accusing a former subsidiary of causing the state to overpay pharmacists for a widely used asthma medication. Attorney General Martha Coakley said Tuesday …Merck to pay Mass. $24M in Medicaid…
-
Merck Dulera shows efficacy in COPD treatment – Pharmaceutical Business Review
Merck Dulera shows efficacy in COPD treatmentPharmaceutical Business ReviewDulera Inhalation Aerosol, which is used to treat asthma combines mometasone furoate, an inhaled corticosteroid, and formoterol fumarate, a long-acting beta2-agonist. The two 26-week, multicenter, double-blind, placebo controlled trials comprising 2251 …Merck Announces Presentation of Phase III Investigational Studies Evaluating …MarketWatch (press release)all 12 news articles » View…
-
Merck Announces Presentation of Phase III Investigational Studies Evaluating … – MarketWatch (press release)
Merck Announces Presentation of Phase III Investigational Studies Evaluating …MarketWatch (press release)DULERA is indicated in the United States for the treatment of asthma in patients 12 years and older.(1) It is not indicated for the relief of acute bronchospasm or for the treatment of COPD. A supplemental new drug application (sNDA) for DULERA for the…